UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2025.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F:
|
Form 20-F
|
☒ |
Form 40-F
|
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
GH Research PLC (the “Company”) recently announced its attendance at the American Society of Clinical Psychopharmacology (“ASCP”) Annual Meeting, which
is scheduled to take place from May 27-30, 2025, in Scottsdale, Arizona (the “Congress”).
The Company will deliver a presentation as part of the Pharmaceutical Pipeline session during the Congress.
A copy of the presentation to be delivered during the Pharmaceutical Pipeline session, presented by Michael E. Thase, is attached hereto as Exhibit 99.1.
1
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
Presentation to be delivered by Michael E. Thase with Title: Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind,
Randomized Controlled Trial
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
GH Research PLC
|
||
|
Date: May 27, 2025
|
||
|
By:
|
/s/ Julie Ryan
|
|
|
Name:
|
Julie Ryan
|
|
|
Title:
|
Vice President, Finance
|
|
3